Search

… Wednesday, April 19, 2023 Memorial Sloan Kettering Cancer Center (MSK) experts presented findings from their latest clinical, translational, and foundational cancer research at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14 to 19 in Orlando, Florida. Highlights

Get to know Abby Hawk, who got a tattoo of Memorial Sloan Kettering after being treated there for neuroblastoma.

… Friday, September 10, 2021 VIDEO | 00:04 Abby Leaves Her Mark Abby's tattoo shows the latitude and longitude of Memorial Sloan Kettering Cancer Center and the quote "The comeback is always stronger than the setback." Video Details It was a bold request. A high school senior living outside Toledo named

David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients drives him to develop more-effective, personalized cancer treatments.

… Tuesday, May 27, 2014 Summary David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients drives him to develop more-effective, personalized cancer treatments. David Solit became a doctor because he wanted to care for patients

Read about why Jae Park joined his colleagues at MSK and New York-Presbyterian to publicly show a united stance against hate.

… Thursday, April 1, 2021 MSK hematologic oncologist Jae Park Jae Park Female doctor wearing a mask and surrounded by her colleagues A large group of doctors and nurses congregating Four doctors wearing white coats and masks A large group of doctors and nurses congregating Over the past few weeks, Jae

Charles Sawyers, MD, Director of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center and a Howard Hughes Medical Institute investigator, has been named a "Dream Team" leader by Stand Up To Cancer and will co-lead a collaborative team that will receive $15 million to study targeted therapies to treat women's cancers.

… Wednesday, May 27, 2009 Charles Sawyers , MD, Director of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center (MSKCC) and a Howard Hughes Medical Institute investigator, has been named a “Dream Team” leader by Stand Up To Cancer and will co-lead a collaborative team

Despite the recent development of novel hormonal therapies - such as enzalutamide and abiraterone - directed at the androgen receptor in the management of castration-resistant prostate cancer, a proportion of men have disease that progresses on these drugs.

… Monday, June 5, 2017 Despite the recent development of novel hormonal therapies - such as enzalutamide and abiraterone - directed at the androgen receptor in the management of castration-resistant prostate cancer, a proportion of men have disease that progresses on these drugs. In this video Dr. Howard

In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study being presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The study will also be published in a corresponding issue of JAMA Oncology.

… Monday, June 5, 2017 In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study being presented at the 2017 annual

This research is important for developing better drugs and screening methods for pancreatic tumors.

… Monday, September 3, 2018 Summary Understanding how pancreatic cancer develops is important for developing better drugs and screening methods. Researchers are finding new clues by studying abnormal pancreas cells that sometimes turn into cancer. One universal truth about cancer is that the later it’s

MSK investigators find that the presence of certain gene mutations in patients’ blood may mean they are more likely to get a secondary leukemia.

… Thursday, August 10, 2017 Summary MSK investigators have found that the presence of certain gene mutations in patients’ blood may mean they are more likely to get a secondary leukemia. The discovery may lead to new methods for determining who is at greatest risk. One of the most devastating things that

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Thursday, May 7, 2020 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Tsvi Gal Is Named MSK’s Head of Infrastructure Tsvi Gal Tsvi Gal Tsvi Gal has been appointed Head of Infrastructure of MSK. Mr. Gal assumed his role on April 28. Mr. Gal will lead the hospital